Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Beth Israel
mi
from
New York, NY
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Beth Israel
mi
from
New York, NY
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Delray Medical Center
mi
from
Delray Beach, FL
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Delray Medical Center
mi
from
Delray Beach, FL
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
CentraCare St. Cloud Hospital
mi
from
Saint Cloud, MN
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
CentraCare St. Cloud Hospital
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
University of New Mexico School of Medicine, Department of Neurosurgery
mi
from
Albuquerque, NM
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
University of New Mexico School of Medicine, Department of Neurosurgery
mi
from
Albuquerque, NM
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
George Washington University
mi
from
Washington,
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
George Washington University
mi
from
Washington,
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
St. Lukes Marion Bloch Neuroscience Institute
mi
from
Kansas City, MO
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
St. Lukes Marion Bloch Neuroscience Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
St. Luke's University Health Network
mi
from
Bethlehem, PA
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
St. Luke's University Health Network
mi
from
Bethlehem, PA
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Allegheny General Hospital
mi
from
Pittsburgh, PA
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
University of California Irvine Chao Family Cancer Center
mi
from
Orange, CA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
University of California Irvine Chao Family Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente
mi
from
Redwood City, CA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente
mi
from
Redwood City, CA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Smilow Cancer Hospital
mi
from
New Haven, CT
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Smilow Cancer Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
NorthShore University Health System
mi
from
Evanston, IL
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
JFK New Jersey Neuroscience Institute
mi
from
Edison, NJ
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
JFK New Jersey Neuroscience Institute
mi
from
Edison, NJ
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Medical Cancer Institute
mi
from
Knoxville, TN
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Medical Cancer Institute
mi
from
Knoxville, TN
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Austin, TX
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Austin, TX
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Baylor Health Charles Sammons Cancer Center
mi
from
Dallas, TX
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Baylor Health Charles Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center- Memorial Hermann Hospital
mi
from
Houston, TX
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center- Memorial Hermann Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Southern California Permanente Medical Group
mi
from
Los Angeles, CA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Southern California Permanente Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Piedmont Hospital
mi
from
Atlanta, GA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
mi
from
Lake Success, NY
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
mi
from
Lake Success, NY
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hospital
mi
from
New York, NY
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Weil Cornell Medical Center
mi
from
New York, NY
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Weil Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Penn State College of Medicine Hershey Medical Center
mi
from
Hershey, PA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Penn State College of Medicine Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Ivy Center for Advanced Brain Tumor Treatment Swedish Medical Center
mi
from
Seattle, WA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Ivy Center for Advanced Brain Tumor Treatment Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Augusta University
mi
from
Augusta, GA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Institute
mi
from
Stanford, CA
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated:  12/31/1969
Delray Medical Center
mi
from
Boca Raton, FL
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status: Enrolling
Updated: 12/31/1969
Delray Medical Center
mi
from
Boca Raton, FL
Click here to add this to my saved trials